Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12568257 | 0.92 | RAB9A (0.43) | NPC1RAB9ALMNASMN1; SMN2MDM2 | |
| SCHEMBL26687954 | 0.91 | NPC1 (0.42) | NPC1RAB9ALMNASMN1; SMN2MDM2 | |
| SCHEMBL14123991 | 0.90 | NPC1 (0.44) | NPC1RAB9ALMNASMN1; SMN2MDM2 | |
| SCHEMBL29454419 | 0.90 | NPC1 (0.45) | NPC1RAB9ALMNAMDM2TP53 | |
| SCHEMBL5813924 | 0.89 | NPC1 (0.43) | NPC1RAB9ALMNASMN1; SMN2MDM2 | |
| SCHEMBL14360219 | 0.89 | NPC1 (0.43) | NPC1RAB9ALMNASMN1; SMN2MDM2 | |
| SCHEMBL31146900 | 0.88 | KMT2A (0.45) | NPC1RAB9ALMNASMN1; SMN2MDM2 | |
| SCHEMBL1745934 | 0.88 | KMT2A (0.45) | NPC1RAB9ALMNASMN1; SMN2MDM2 | |
| SCHEMBL14416300 | 0.88 | KMT2A (0.42) | NPC1RAB9ALMNASMN1; SMN2MDM2 | |
| SCHEMBL29470540 | 0.88 | KMT2A (0.45) | NPC1RAB9ALMNASMN1; SMN2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | GLP1R, GIPR, GRPR | NPC1 1052/4885RAB9A 1594/4885LMNA 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.